<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Jeffrey A. Setaro&#187; Anna Schwartz</title>
	<atom:link href="http://www.jasetaro.com/blog/tag/anna-schwartz/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.jasetaro.com/blog</link>
	<description>Political &#38; Cultural Commentary from a Constitutional Conservative.</description>
	<lastBuildDate>Tue, 07 Feb 2012 18:57:14 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Weekend Recap</title>
		<link>http://www.jasetaro.com/blog/2008/10/20/weekend-recap/</link>
		<comments>http://www.jasetaro.com/blog/2008/10/20/weekend-recap/#comments</comments>
		<pubDate>Mon, 20 Oct 2008 17:09:01 +0000</pubDate>
		<dc:creator>Jeff</dc:creator>
				<category><![CDATA[Economy]]></category>
		<category><![CDATA[Medicine]]></category>
		<category><![CDATA[Politics]]></category>
		<category><![CDATA[Anna Schwartz]]></category>
		<category><![CDATA[Barack Obama]]></category>
		<category><![CDATA[Drug Reseasrch]]></category>
		<category><![CDATA[Economic Crisis]]></category>
		<category><![CDATA[Scott Gottlieb]]></category>

		<guid isPermaLink="false">http://www.jasetaro.com/blog/?p=811</guid>
		<description><![CDATA[For the most part I stayed away from the computer and the news this weekend. I did come across a couple of must reads in the Wall Street Journal though. The first is Brian Carney&#8217;s weekend interview with Anna Schwartz, Ms. Schwartz is well known economist and her views on the current economic crisis are [...]]]></description>
			<content:encoded><![CDATA[<p>For the most part I stayed away from the computer and the news this weekend. I did come across a couple of must reads in the Wall Street Journal though.</p>
<p>The first is Brian Carney&#8217;s weekend interview with Anna Schwartz, Ms. Schwartz is well known economist and her views on the current economic crisis are quite interesting.</p>
<blockquote>
<h3>Bernanke Is Fighting the Last War</h3>
<p>&#8216;Everything works much better when wrong decisions are  punished and good decisions make you rich.&#8217;</p>
<p>By BRIAN  M. CARNEY</p>
<p>On Aug. 9, 2007, central banks around the world first intervened to stanch  what has become a massive credit crunch.</p>
<p>Since then, the Federal Reserve and the Treasury have taken a series of  increasingly drastic emergency actions to get lending flowing again. The central  bank has lent out hundreds of billions of dollars, accepted collateral that in  the past it would never have touched, and opened direct lending to institutions  that have never had that privilege. The Treasury has deployed billions more. And  yet, &#8220;Nothing,&#8221; Anna Schwartz says, &#8220;seems to have quieted the fears of either  the investors in the securities markets or the lenders and would-be borrowers in  the credit market.&#8221;</p>
<p>The credit markets remain frozen, the stock market continues to get hammered,  and deep recession now seems a certainty &#8212; if not a reality already.</p>
<p>Most people now living have never seen a credit crunch like the one we are  currently enduring. Ms. Schwartz, 92 years old, is one of the exceptions. She&#8217;s  not only old enough to remember the period from 1929 to 1933, she may know more  about monetary history and banking than anyone alive. She co-authored, with  Milton Friedman, &#8220;A Monetary History of the United States&#8221; (1963). It&#8217;s the  definitive account of how misguided monetary policy turned the stock-market  crash of 1929 into the Great Depression.</p>
<p>Since 1941, Ms. Schwartz has reported for work at the National Bureau of  Economic Research in New York, where we met Thursday morning for an interview.  She is currently using a wheelchair after a recent fall and laments her &#8220;many  infirmities,&#8221; but those are all physical; her mind is as sharp as ever. She  speaks with passion and just a hint of resignation about the current financial  situation. And looking at how the authorities have handled it so far, she  doesn&#8217;t like what she sees.</p>
<p>Federal Reserve Chairman Ben Bernanke has called the 888-page &#8220;Monetary  History&#8221; &#8220;the leading and most persuasive explanation of the worst economic  disaster in American history.&#8221; Ms. Schwartz thinks that our central bankers and  our Treasury Department are getting it wrong again.</p>
<p>To understand why, one first has to understand the nature of the current  &#8220;credit market disturbance,&#8221; as Ms. Schwartz delicately calls it. We now hear  almost every day that banks will not lend to each other, or will do so only at  punitive interest rates. Credit spreads &#8212; the difference between what it costs  the government to borrow and what private-sector borrowers must pay &#8212; are at  historic highs. <a href="http://online.wsj.com/article/SB122428279231046053.html" target="_blank">Read the rest&#8230;</a></p></blockquote>
<p>The Second is Scott  Gottlieb&#8217;s Op Ed on Drug research, Dr. Gottlieb is a practicing physician and a resident fellow at the American  Enterprise Institute, his column examines how government policies are stifling research into drugs to treat common medical problems.</p>
<div class="col10wide wrap">
<div class="articleHeadlineBox headlineType-newswire">
<blockquote>
<h3>How Obama Would Stifle Drug Innovation</h3>
<p>If you want cutting-edge health care, don&#8217;t make it a  cost-controlled commodity.</p>
<p>By SCOTT  GOTTLIEB</p>
<p>Pfizer recently said it&#8217;s exiting the development of drugs for common  conditions like heart disease. This is part of a shift underway in the  pharmaceutical industry to give up on routine medical problems in favor of  discovering &#8220;specialty&#8221; drugs for rare diseases and unmet medical needs like  cancer.</p>
<p>The shift is driven in part by the industry&#8217;s critics in Washington, who have  long maligned drug companies for targeting too many routine medical problems  with drugs that were &#8220;merely&#8221; tweaks on existing medicines. Now these same  detractors, led by House Democrats, are proposing controls on access to and  eventually pricing of the specialty drugs as well. Under a Barack Obama  presidency, this is one way they&#8217;ll pay for the candidate&#8217;s plan to create a  Medicare-like program for the under-65 crowd. These new controls &#8212; based on a  view of medical care as a commodity to be purchased at the lowest price, with  little allowance for innovation &#8212; could push drug development over a tipping  point.</p>
<p>Specialty drugs offer significant health benefits but for a high price,  reflecting the difficulty of developing them. The regulatory process for getting  them approved is more uncertain, since the diseases are poorly understood or  haven&#8217;t been tackled before in clinical trials. Enrolling patients with rare  conditions is also expensive; they are harder to recruit and often need to  undergo more extensive testing to monitor the progress in trials. It can cost  less than $5,000 to enroll a single patient in a trial for a primary care drug  such as a blood pressure pill, but up to $70,000 for a big cancer study and more  than $100,000 for some very rare diseases. Specialty drugs that were once tested  on hundreds of patients are now often required by the Food and Drug  Administration (FDA) to be tested on thousands.</p>
<p>Success rates are low. On average, a drug stands an 11% chance of making it  through clinical trials and reaching patients. Cancer drugs only have a 5%  chance of clearing these hurdles. Specialty drugs are also harder to distribute  and by definition have a much smaller market for sales. <a href="http://online.wsj.com/article/SB122428260748146061.html" target="_blank">Read the rest&#8230;</a></p></blockquote>
</div>
</div>
]]></content:encoded>
			<wfw:commentRss>http://www.jasetaro.com/blog/2008/10/20/weekend-recap/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

